Supernus Pharmaceuticals, Inc. (SUPN) investor relations documents from the company's IR site: 2 presentations, 16 press releases; latest deck 2026-08-03. Read in-app with summaries. First-party data.
Merger of Equals to Create a Diversified CNS Biopharmaceutical Leader with Significant Scale: Merger of equals between Supernus and Indivior to create a diversified CNS biopharmaceutical leader with $2.2Bn in pro-forma net revenues and expected annual cost synergies of at
SUPN overview · SUPN earnings · SUPN financials · SUPN KPIs · SUPN documents · SUPN ownership · SUPN peers
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.